Preventing cardiovascular events with angiotensin II receptor blockers: A closer look at telmisartan and valsartan

Massimo Volpe

Research output: Contribution to journalArticlepeer-review

Abstract

Angiotensin II receptor blockers (ARBs) inhibit the renin-angiotensin system. As a result, these agents provide beneficial effects in terms of cardiovascular (CV) and renal protection, independent of their blood pressure-lowering effects. Telmisartan and valsartan are the most intensively studied ARBs for the effects on CV outcomes. Randomized clinical trials assessing morbidity and mortality end points have included a range of patient types, including those with hypertension, hypertension with Type 2 diabetes, high CV risk without hypertension, ischemic heart disease, stroke and heart failure. Few head-to-head comparisons between telmisartan and valsartan have been performed. However, some blood pressure-independent properties of these two ARBs can be scrutinized from separate studies in the available literature.

Original languageEnglish
Pages (from-to)1061-1072
Number of pages12
JournalExpert Review of Cardiovascular Therapy
Volume10
Issue number8
DOIs
Publication statusPublished - Aug 2012

Keywords

  • angiotensin II receptor blockers
  • cardiovascular outcomes
  • hypertension
  • renin-angiotensin system
  • telmisartan
  • valsartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Fingerprint

Dive into the research topics of 'Preventing cardiovascular events with angiotensin II receptor blockers: A closer look at telmisartan and valsartan'. Together they form a unique fingerprint.

Cite this